Retatrutide vs Semaglutide: How Do They Compare for Weight Loss?
By FormBlends Medical Team · Last updated: April 6, 2026
Semaglutide remains the gold standard if safety data and cardiovascular benefit matter to you. The SELECT trial is the only weight-loss trial ever to show a 20% reduction in heart attacks and strokes in non-diabetic patients. Retatrutide produces more weight loss in head-to-head Phase 2 data, but it doesn't have cardiovascular outcomes data or FDA approval yet. For most patients, starting with semaglutide and considering a switch to retatrutide (once approved) makes the most sense.
How to Use This Comparison
Use this comparison as a decision aid, not a prescription shortcut. Weight loss: retatrutide ~24% vs semaglutide ~15% (different trial designs). Retatrutide is usually a better fit for people looking for maximum weight loss potential who are comfortable with a newer, investigational compound, while Semaglutide is usually a better fit for people who want the most proven, extensively studied glp-1 option with cardiovascular benefit data and long-term safety evidence. Cost also matters: Retatrutide is listed at $350-600/month (compounded), while Semaglutide is listed at $200-350/month (compounded), $1,000-1,500/month (brand). Because this comparison is framed as an either-or decision, the safety question is which option fits your health history, side-effect tolerance, and access path.
FormBlends Comparison Context
Reviewed May 14, 2026Read Retatrutide Vs Semaglutide comparison with the practical follow-up in mind. If the topic involves GLP-1 treatment, provider comparison, the next useful step is usually to verify evidence strength, access rules, pharmacy pathway, total cost, and the personal safety details that only a clinician can review.
- Confirm whether the page is discussing approved care, compounded access, off-label use, or research-only context.
- Check the date, evidence quality, safety limits, and whether newer clinical or regulatory updates may change the answer.
- Ask a licensed clinician how the information applies to your history, medications, labs, goals, and risk profile.
PubMed evidence trail
Research sources used to frame this page
For Retatrutide vs Semaglutide: How Do They Compare for Weight Loss?, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
Supports SELECT-context pages where semaglutide claims touch long-term weight change and cardiovascular-risk populations.
PubMed
Semaglutide for cardiovascular event reduction in people with overweight or obesity
Baseline SELECT source for cardiovascular-outcomes framing in people with overweight or obesity.
PubMed
Comparison decision path
Use this comparison to narrow the provider review question
Direct answer
Retatrutide vs Semaglutide: How Do They Compare for Weight Loss? should help you decide which option deserves a clinical review, not force a one-size answer.
Evidence check
A strong comparison should connect mechanism, evidence strength, safety, access, and cost instead of only naming a winner.
Safety check
The right choice can change based on history, medication interactions, side effects, budget, and availability.
Next step
After comparing, use the get-started flow to route your goals and health history into the right prescription review path.
Head-to-Head Comparison
Retatrutide
GLP-1 Triple Agonist
Strengths
- Triple receptor agonist (GLP-1 + GIP + glucagon)
- Phase 2 showed up to 24.2% weight loss at 48 weeks
- Glucagon activation may improve liver fat clearance
- Once-weekly dosing
Weaknesses
- Not yet FDA-approved
- Only Phase 2 data available (N=338)
- Long-term safety unknown
- More expensive through compounding
- Higher rate of GI side effects in trials
Best For
People looking for maximum weight loss potential who are comfortable with a newer, investigational compound.
Typical Cost
$350-600/month (compounded)
Semaglutide
GLP-1 Agonist
Strengths
- FDA-approved as Wegovy (weight loss) and Ozempic (diabetes)
- STEP 1 trial (N=1,961) showed 14.9% average weight loss
- SELECT trial (N=17,604) proved 20% cardiovascular risk reduction
- Most extensively studied GLP-1 for weight loss
- Available as brand and compounded
- Longest real-world safety track record among GLP-1s
Weaknesses
- Single receptor (GLP-1 only) produces less weight loss than dual/triple agonists
- Brand-name cost is high without insurance ($1,000-1,500/month)
- GI side effects during titration
- Some patients hit a weight loss plateau at 12-15%
Best For
People who want the most proven, extensively studied GLP-1 option with cardiovascular benefit data and long-term safety evidence.
Typical Cost
$200-350/month (compounded), $1,000-1,500/month (brand)
Key Differences
- 1Weight loss: retatrutide ~24% vs semaglutide ~15% (different trial designs)
- 2Receptor targets: triple (retatrutide) vs single (semaglutide)
- 3FDA status: semaglutide approved, retatrutide investigational
- 4CV data: semaglutide has the landmark SELECT trial; retatrutide has none
- 5Trial maturity: semaglutide has 30,000+ trial participants across programs; retatrutide has 338
Frequently Asked Questions
What is the difference between Retatrutide and Semaglutide?
Weight loss: retatrutide ~24% vs semaglutide ~15% (different trial designs). Receptor targets: triple (retatrutide) vs single (semaglutide).
Which is more effective, Retatrutide or Semaglutide?
Semaglutide remains the gold standard if safety data and cardiovascular benefit matter to you. The SELECT trial is the only weight-loss trial ever to show a 20% reduction in heart attacks and strokes in non-diabetic patients. Retatrutide produces more weight loss in head-to-head Phase 2 data, but it doesn't have cardiovascular outcomes data or FDA approval yet. For most patients, starting with semaglutide and considering a switch to retatrutide (once approved) makes the most sense.
How much does Retatrutide cost compared to Semaglutide?
Retatrutide typically costs $350-600/month (compounded), while Semaglutide typically costs $200-350/month (compounded), $1,000-1,500/month (brand).
Who should choose Retatrutide over Semaglutide?
Retatrutide is best for: People looking for maximum weight loss potential who are comfortable with a newer, investigational compound.. Semaglutide is best for: People who want the most proven, extensively studied GLP-1 option with cardiovascular benefit data and long-term safety evidence..
Ready to get started?
Connect with a licensed provider who can help you decide between Retatrutide and Semaglutide based on your goals, health history, and budget.